Literature DB >> 33374507

The Importance of Non-Coding RNAs in Neurodegenerative Processes of Diabetes-Related Molecular Pathways.

Joanna Jarosz-Popek1, Marta Wolska1, Aleksandra Gasecka2, Pamela Czajka1, Daniel Jakubik1, Lucia Sharif1, Taqwa Adem1, Wei-Ling Liu1, Dagmara Mirowska-Guzel1, Marek Postula1, Ceren Eyileten1.   

Abstract

Diabetes mellitus (DM) is a complex condition and serious health problem, with growing occurrence of DM-associated complications occurring globally. Persistent hyperglycemia is confirmed as promoting neurovascular dysfunction leading to irreversible endothelial cell dysfunction, increased neuronal cell apoptosis, oxidative stress and inflammation. These collaboratively and individually result in micro- and macroangiopathy as well as neuropathy demonstrated by progressive neuronal loss. Recently, major efforts have been pursued to select not only useful diagnostic and prognostic biomarkers, but also novel therapeutic approaches. Both microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) belong to a class of non-coding RNAs identified in most of the body fluids i.e., peripheral blood, cerebrospinal fluid, brain tissue and neurons. Numerous miRNAs, lncRNAs and their target genes are able to modulate signaling pathways known to play a role in the pathophysiology of progressive neuronal dysfunction. Therefore, they pose as promising biomarkers and treatment for the vast majority of neurodegenerative disorders. This review provides an overall assessment of both miRNAs' and lncRNAs' utility in decelerating progressive nervous system impairment, including neurodegeneration in diabetic pathways.

Entities:  

Keywords:  biomarker; lncRNA; miR; miRNA; non-coding RNA; novel biomarker; treatment

Year:  2020        PMID: 33374507     DOI: 10.3390/jcm10010009

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  5 in total

1.  Genetic Variants Associated with Neuropeptide Y Autoantibody Levels in Newly Diagnosed Individuals with Type 1 Diabetes.

Authors:  Sara Juul Mansachs; Sofie Olund Villumsen; Jesper Johannesen; Alexander Lind; Simranjeet Kaur; Flemming Pociot
Journal:  Genes (Basel)       Date:  2022-05-12       Impact factor: 4.141

Review 2.  MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics.

Authors:  Daniel Jakubik; Alex Fitas; Ceren Eyileten; Joanna Jarosz-Popek; Anna Nowak; Pamela Czajka; Zofia Wicik; Harald Sourij; Jolanta M Siller-Matula; Salvatore De Rosa; Marek Postula
Journal:  Cardiovasc Diabetol       Date:  2021-02-27       Impact factor: 9.951

Review 3.  MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review.

Authors:  Pamela Czajka; Alex Fitas; Daniel Jakubik; Ceren Eyileten; Aleksandra Gasecka; Zofia Wicik; Jolanta M Siller-Matula; Krzysztof J Filipiak; Marek Postula
Journal:  Front Physiol       Date:  2021-04-15       Impact factor: 4.566

4.  Altered Circulating MicroRNA Profiles After Endurance Training: A Cohort Study of Ultramarathon Runners.

Authors:  Ceren Eyileten; Zofia Wicik; Alex Fitas; Mikolaj Marszalek; Jenny E Simon; Salvatore De Rosa; Szczepan Wiecha; Jeffrey Palatini; Marek Postula; Lukasz A Malek
Journal:  Front Physiol       Date:  2022-01-25       Impact factor: 4.566

5.  Thrombosis-related circulating miR-16-5p is associated with disease severity in patients hospitalised for COVID-19.

Authors:  Ceren Eyileten; Zofia Wicik; Sérgio N Simões; David C Martins-Jr; Krzysztof Klos; Wojciech Wlodarczyk; Alice Assinger; Dariusz Soldacki; Andrzej Chcialowski; Jolanta M Siller-Matula; Marek Postula
Journal:  RNA Biol       Date:  2022-01       Impact factor: 4.766

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.